Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.57 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16615511 | 0.89 | KCNQ2 (0.67) | LMNAMAPTGAASMN1; SMN2KCNQ2 | |
| SCHEMBL16615486 | 0.88 | KCNQ2 (0.66) | LMNAMAPTSMN1; SMN2KCNQ2KMT2A | |
| SCHEMBL16615537 | 0.87 | ALDH1A1 (0.60) | SMN1; SMN2KCNQ2KMT2AMEN1ALDH1A1 | |
| SCHEMBL16615846 | 0.86 | ALDH1A1 (0.70) | LMNAMAPTSMN1; SMN2KCNQ2KMT2A | |
| SCHEMBL21164696 | 0.81 | LMNA (0.65) | LMNAMAPTGAANPSR1SMN1; SMN2 | |
| SCHEMBL9138268 | 0.77 | ALDH1A1 (0.68) | LMNAMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL18181909 | 0.76 | NPC1 (0.70) | LMNAMAPTGAANPSR1KMT2A | |
| SCHEMBL16615822 | 0.75 | ALDH1A1 (0.66) | LMNAMAPTSMN1; SMN2KCNQ2KMT2A | |
| SCHEMBL16615791 | 0.75 | ALDH1A1 (0.65) | LMNAMAPTSMN1; SMN2KCNQ2KMT2A | |
| SCHEMBL19074542 | 0.74 | ALDH1A1 (0.82) | LMNAMAPTSMN1; SMN2KCNQ2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160213679-A1 | INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF | Université de Montréal (CA) | 2016-07-28 | — | — | US | disclosed |
| US-20160213679-A1 | INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF | Université de Montréal (CA) | 2016-07-28 | — | — | US | disclosed |
| WO-2015042685-A1 | INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF | VALORISATION-RECHERCHE (CA) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213679-A1 | INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF | FBL, HNRNPA1, HNRNPUL1 | LMNA 705/4885MAPT 417/4885GAA 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.